miR‑489‑3p inhibits TLR4/NF‑κB signaling to prevent inflammation in psoriasis
- Yujian Ye
- Ping Wang
- Fangmei Zhou
Affiliations: Department of Dermatology, The Third People's Hospital of Hangzhou, Hangzhou, Zhejiang 310009, P.R. China, College of Medical Technology, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, P.R. China
- Published online on: May 11, 2021 https://doi.org/10.3892/etm.2021.10176
Copyright: © Ye
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Psoriasis is a chronic inflammatory skin disease whose etiology has not yet been determined. MicroRNAs (miRs) regulate the early stages of psoriasis and are targets for therapeutic intervention. The present study aimed to investigate the functional role of miR‑489‑3p in psoriasis. The present study first assessed the expression levels of miR‑489‑3p and Toll‑like receptor (TLR)4 mRNA using reverse transcription‑quantitative PCR, and also detected the protein expression levels of TLR4 and NF‑κB via western blot analysis. TargetScan and miRDB target gene prediction tools were used to confirm the regulation of Toll‑like receptor (TLR)4 by miR‑489‑3p. Moreover, a Cell Counting Kit (CCK)‑8 assay was conducted to evaluate cell viability, while cell cycle and colony formation assays were performed to evaluate cell proliferation. Human keratinocytes (HaCaT) were co‑transfected with TLR4‑small interfering RNA and miR‑489‑3p‑inhibitor plasmids, and analysis of cell proliferation and inflammatory cytokine secretion was performed using CCK‑8 assay and ELISA. It was found that miR‑489‑3p expression was downregulated in patients with psoriasis. Bioinformatics analysis identified that TLR4 was a direct target of miR‑489‑3p. This was confirmed via luciferase reporter assays in HaCaT cells. The overexpression of miR‑489‑3p inhibited the TLR4/NF‑κB signaling pathway and reduced cell proliferation. TLR4 silencing alleviated the effects of miR‑489‑3p, and enhanced cell proliferation and inflammatory cytokine secretion. Taken together, these data suggested that miR‑489‑3p may be a key effector of psoriasis, which promotes inflammatory responses by direct targeting of TLR4. miR‑489‑3p therefore represents a promising prognostic biomarker and therapeutic target for psoriasis treatment.